DE602004025159D1 - Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen - Google Patents
Matrixzubereitungen für die kontrollierte Darreichung von ArzneistoffenInfo
- Publication number
- DE602004025159D1 DE602004025159D1 DE602004025159T DE602004025159T DE602004025159D1 DE 602004025159 D1 DE602004025159 D1 DE 602004025159D1 DE 602004025159 T DE602004025159 T DE 602004025159T DE 602004025159 T DE602004025159 T DE 602004025159T DE 602004025159 D1 DE602004025159 D1 DE 602004025159D1
- Authority
- DE
- Germany
- Prior art keywords
- polymer
- polyethylene
- ethylene
- matrix composition
- styrene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011159 matrix material Substances 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 6
- 239000011248 coating agent Substances 0.000 abstract 3
- 238000000576 coating method Methods 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 3
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 abstract 2
- 229920001577 copolymer Polymers 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- -1 polyethylene Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 abstract 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 abstract 1
- 239000004952 Polyamide Substances 0.000 abstract 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 229920000954 Polyglycolide Polymers 0.000 abstract 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004809 Teflon Substances 0.000 abstract 1
- 229920006362 Teflon® Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000005038 ethylene vinyl acetate Substances 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000004816 latex Substances 0.000 abstract 1
- 229920000126 latex Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 abstract 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 abstract 1
- 229920000747 poly(lactic acid) Polymers 0.000 abstract 1
- 229920002647 polyamide Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 229920000139 polyethylene terephthalate Polymers 0.000 abstract 1
- 239000005020 polyethylene terephthalate Substances 0.000 abstract 1
- 239000004633 polyglycolic acid Substances 0.000 abstract 1
- 239000004626 polylactic acid Substances 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 229920002635 polyurethane Polymers 0.000 abstract 1
- 239000004814 polyurethane Substances 0.000 abstract 1
- 229920002689 polyvinyl acetate Polymers 0.000 abstract 1
- 239000011118 polyvinyl acetate Substances 0.000 abstract 1
- 229920000915 polyvinyl chloride Polymers 0.000 abstract 1
- 239000004800 polyvinyl chloride Substances 0.000 abstract 1
- 229920002379 silicone rubber Polymers 0.000 abstract 1
- 239000004945 silicone rubber Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300464 | 2003-03-26 | ||
PCT/DK2003/000765 WO2004041252A1 (en) | 2002-11-08 | 2003-11-07 | Controlled release carvedilol compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004025159D1 true DE602004025159D1 (de) | 2010-03-04 |
Family
ID=33099580
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004025159T Expired - Lifetime DE602004025159D1 (de) | 2003-03-26 | 2004-03-26 | Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen |
DE602004014747T Expired - Lifetime DE602004014747D1 (de) | 2003-03-26 | 2004-03-26 | Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004014747T Expired - Lifetime DE602004014747D1 (de) | 2003-03-26 | 2004-03-26 | Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen |
Country Status (9)
Country | Link |
---|---|
US (2) | US8298581B2 (de) |
EP (3) | EP1974726B1 (de) |
JP (1) | JP4989217B2 (de) |
AT (2) | ATE399538T1 (de) |
CA (1) | CA2520312C (de) |
DE (2) | DE602004025159D1 (de) |
DK (1) | DK1610768T3 (de) |
ES (1) | ES2307003T3 (de) |
WO (1) | WO2004084869A1 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2327685C (en) * | 1998-04-03 | 2008-11-18 | Bm Research A/S | Controlled release composition |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20040151772A1 (en) * | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
CA2520312C (en) * | 2003-03-26 | 2013-06-18 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
AU2006254554B2 (en) * | 2005-06-03 | 2011-11-24 | Egalet Ltd | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
WO2007084212A2 (en) * | 2006-01-19 | 2007-07-26 | Dow Global Technologies Inc. | Biologically active composition comprising ethylcellulose |
EP2104493A2 (de) * | 2007-01-16 | 2009-09-30 | Egalet A/S | Verwendung i) eines polyglycols und n) einer wirkstoffsubstanz zur herstellung einer pharmazeutischen zusammensetzung i) zur abschwächung des risikos alkoholbedingten dose-dumpings und/oder ii) zur reduzierung des risikos eines medikamentenmissbrauchs |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
KR100932613B1 (ko) * | 2007-04-27 | 2009-12-17 | 한남대학교 산학협력단 | 고분자 용융공정을 이용한 약물전달용 생체적합성 고분자나노 미립구의 제조방법 및 그 나노 미립구 |
EP2155167A2 (de) | 2007-06-04 | 2010-02-24 | Egalet A/S | Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung |
US7940978B2 (en) * | 2007-06-05 | 2011-05-10 | General Electric Company | Automatic characterization of cellular motion |
US8501230B2 (en) * | 2007-12-03 | 2013-08-06 | Trilogic Pharma Llc | Self solidifying bioerodible barrier implant |
US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
EP2259803B2 (de) | 2008-02-29 | 2019-03-13 | Ferrosan Medical Devices A/S | Vorrichtung zur förderung von hämostase und/oder wundheilung |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t |
JP2011524353A (ja) * | 2008-06-10 | 2011-09-01 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリン軟ゼラチンカプセル |
EP2309991B1 (de) | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutische polymernanopartikel mit vincaalkaloiden sowie verfahren zu ihrer herstellung und verwendung |
KR101706178B1 (ko) | 2008-06-16 | 2017-02-15 | 화이자 인코포레이티드 | 약물 부하된 중합체성 나노입자, 및 이의 제조 및 사용 방법 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US20110250274A1 (en) * | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
US8563041B2 (en) * | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
WO2010088911A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Pharmaceutical compositions resistant to abuse |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
KR101738369B1 (ko) | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | 핫 멜트 압출된 제어 방출 투여형 |
RU2555531C2 (ru) | 2009-07-22 | 2015-07-10 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма для чувствительных к окислению опиоидов |
EP3064064A1 (de) | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur abschreckung vor missbrauch |
JP5891175B2 (ja) | 2009-12-11 | 2016-03-22 | バインド セラピューティックス インコーポレイテッド | 治療用粒子の凍結乾燥に対する安定製剤 |
EP2515942B1 (de) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutische polymernanopartikelzusammensetzungen mit hoher glasübergangstemperatur oder copolymeren von hohem molekulargewicht |
CA2790248A1 (en) | 2010-03-15 | 2011-09-22 | Ferrosan Medical Devices A/S | A method for promotion of hemostasis and/or wound healing |
US10039709B2 (en) | 2010-06-04 | 2018-08-07 | Trilogic Pharma Llc | Bioadhesive compositions for epithelial drug delivery |
EP2611426B1 (de) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Manipulationssichere darreichungsform mit einem anorganischen salz |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
JP2013543844A (ja) * | 2010-10-22 | 2013-12-09 | バインド セラピューティックス インコーポレイテッド | 高分子コポリマーを含む治療用ナノ粒子 |
KR101775727B1 (ko) | 2010-12-15 | 2017-09-19 | 가톨릭대학교 산학협력단 | 폴리알킬렌글리콜-링커-폴리에스터 공중합체, 그 제조방법 및 용도 |
AR087359A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco |
EA201400172A1 (ru) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства |
TWI641396B (zh) | 2011-09-23 | 2018-11-21 | Bvw控股公司 | 醫療共聚物 |
EP2819656A1 (de) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Fälschungssichere dosierform mit einer pharmazeutisch aktiven verbindung und einem anionischen polymer |
WO2013127830A1 (en) * | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
IN2014DN08122A (de) | 2012-03-06 | 2015-05-01 | Ferrosan Medical Devices As | |
MX362357B (es) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis. |
KR101455901B1 (ko) * | 2012-05-04 | 2014-11-03 | 성균관대학교산학협력단 | 세레콕시브 및 폴록사머를 포함하는 공융 혼합물 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EP2977066A3 (de) | 2012-06-12 | 2016-07-27 | Ferrosan Medical Devices A/S | Trockene blutstillende zusammensetzung |
CA2877183A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
CA2885193C (en) | 2012-09-17 | 2021-04-27 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
EP3446685A1 (de) | 2012-11-30 | 2019-02-27 | Acura Pharmaceuticals, Inc. | Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
CA2912357C (en) | 2013-06-21 | 2019-12-31 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
EP3052084A1 (de) * | 2013-09-30 | 2016-08-10 | Universiteit Gent | Polyurethane als orale arzneimittelverabreichungsplattform |
US10350232B1 (en) | 2013-11-04 | 2019-07-16 | Peter D. Jaillet | Medicinal drops |
AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
EP3079731B1 (de) | 2013-12-11 | 2018-08-08 | Ferrosan Medical Devices A/S | Trockenzusammensetzung mit extrusionsverstärker |
US20150164807A1 (en) | 2013-12-16 | 2015-06-18 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile manufactured by co-extrusion |
PL3116547T3 (pl) | 2014-03-14 | 2019-11-29 | Pfizer | Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania |
CA2943728C (en) | 2014-03-26 | 2020-03-24 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
CN107206165B (zh) | 2014-12-24 | 2020-10-23 | 弗罗桑医疗设备公司 | 用于保持并混合第一和第二物质的注射器 |
US10182993B2 (en) * | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
EP3281980B1 (de) * | 2015-04-07 | 2021-03-03 | Mitsubishi Chemical Corporation | Harzzusammensetzung und mehrschichtige struktur damit sowie verfahren zur verbesserung der langfristigen stabilität |
EP3285745A1 (de) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Manipulationssichere darreichungsform mit sofortiger freisetzung und widerstand gegen lösungsmittelextraktion |
US20180177718A1 (en) * | 2015-05-29 | 2018-06-28 | Envisia Therapeutics, Inc. | Implant for treatment of an ocular condition |
RU2717356C2 (ru) | 2015-07-03 | 2020-03-23 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания вакуума в состоянии хранения |
EP3135272A1 (de) * | 2015-08-31 | 2017-03-01 | Basf S.A. | Zusammensetzungen für ein mundspülmittel in tablettenform |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
WO2017099952A1 (en) * | 2015-12-08 | 2017-06-15 | Dow Global Technologies Llc | Compositions comprising cellulose ethers and water-soluble esterified cellulose ethers |
EP3184104B1 (de) * | 2015-12-23 | 2018-09-12 | Hexal AG | Pharmazeutische zusammensetzung von vortioxetin-hydrobromid mit vortioxetinhydrobromid in einer polyethylenoxidmatrix |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
CN117771250A (zh) | 2018-06-29 | 2024-03-29 | 因赛特公司 | Axl/mer抑制剂的制剂 |
KR102538853B1 (ko) * | 2019-10-30 | 2023-06-01 | 주식회사 에이디 | 할로이사이트 펠릿을 페로몬 흡수소재로 사용한 페로몬 방출기 및 그 제조방법 |
CN114796135B (zh) * | 2022-03-29 | 2023-04-07 | 海南久常制药有限公司 | 一种硫糖铝口服制剂及其制备方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1018456A (en) | 1972-06-26 | 1977-10-04 | Hans Lowey | Prolonged release lozenges |
JPS5518694B2 (de) | 1973-04-02 | 1980-05-21 | ||
US4330338A (en) | 1978-10-02 | 1982-05-18 | Purdue Research Foundation | Pharmaceutical coating composition, and preparation and dosages so coated |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
DE3320583A1 (de) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
AU591171B2 (en) | 1983-11-02 | 1989-11-30 | Alza Corporation | Dispenser for delivering thermo-responsive composition |
US4844984A (en) | 1984-03-19 | 1989-07-04 | Alza Corporation | Dispensing system with means for increasing delivery of beneficial agent from the system |
JPH0246008B2 (ja) | 1984-06-01 | 1990-10-12 | Takada Seiyaku Kk | Nifuejipinjizokuseiseizainoseizohoho |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
GB2170104A (en) | 1985-01-30 | 1986-07-30 | Warner Lambert Co | Coated pharmaceutical dosage forms |
IE59066B1 (en) | 1985-02-19 | 1993-12-15 | Key Pharma | Controlled release potassium chloride |
US4892742A (en) | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
US4824675A (en) * | 1987-07-13 | 1989-04-25 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
WO1989009066A1 (en) * | 1988-03-24 | 1989-10-05 | Bukh Meditec A/S | Controlled release composition |
FI101344B1 (fi) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
JPH04503058A (ja) | 1989-01-30 | 1992-06-04 | アルザ コーポレイション | カルシウム拮抗体投与のための剤形 |
DK469989D0 (da) | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
GB9025372D0 (en) | 1990-11-22 | 1991-01-09 | Nat Res Dev | Pharmaceutical dosage forms |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5881926A (en) | 1993-03-11 | 1999-03-16 | Taro Pharmaceutical Industries, Ltd. | Pharmaceutical compositions in semisolid form and a device for administration thereof |
US5656291A (en) * | 1994-03-16 | 1997-08-12 | Pharmacia & Upjohn Aktiebolag | Controlled release preparation |
JPH07100191A (ja) | 1993-10-06 | 1995-04-18 | Daikyo Yakuhin Kogyo Kk | 徐放性坐剤 |
US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
AU1806895A (en) | 1994-02-23 | 1995-09-11 | Bm Research A/S | Controlled release composition |
IL139728A (en) | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
JP3161278B2 (ja) | 1995-04-26 | 2001-04-25 | 株式会社村田製作所 | 誘電体磁器組成物 |
WO1997044034A1 (fr) | 1996-05-20 | 1997-11-27 | Otsuka Pharmaceutical Co., Ltd. | Remede pour le traitement de l'acne rosacee |
ATE197900T1 (de) | 1996-08-15 | 2000-12-15 | Losan Pharma Gmbh | Gut schluckbare orale arzneiform |
US20020054911A1 (en) | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
CA2327685C (en) * | 1998-04-03 | 2008-11-18 | Bm Research A/S | Controlled release composition |
US6395299B1 (en) * | 1999-02-12 | 2002-05-28 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6562375B1 (en) | 1999-08-04 | 2003-05-13 | Yamanouchi Pharmaceuticals, Co., Ltd. | Stable pharmaceutical composition for oral use |
US6534085B1 (en) * | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
JP4310010B2 (ja) * | 1999-10-08 | 2009-08-05 | パナソニック株式会社 | 単位電池 |
US6515010B1 (en) | 1999-11-15 | 2003-02-04 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
US6491949B2 (en) | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US6352721B1 (en) | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
US6378165B1 (en) * | 2000-02-17 | 2002-04-30 | Emerson Electric Co. | Pull handle with interlocking mounting mechanism for wet/dry vacuum appliance |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
WO2002065834A2 (en) | 2000-10-24 | 2002-08-29 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
IN191028B (de) | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
DE10131272B4 (de) * | 2001-06-28 | 2006-03-30 | Koenig & Bauer Ag | Wendevorrichtung |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20050019399A1 (en) | 2001-09-21 | 2005-01-27 | Gina Fischer | Controlled release solid dispersions |
JP2005508325A (ja) * | 2001-09-28 | 2005-03-31 | マクニール−ピーピーシー・インコーポレイテッド | 内側コア及び外側シェルを有する投薬形態 |
AU2003225837B2 (en) * | 2002-03-15 | 2008-11-06 | Forest Laboratories Holdings Limited | NE and 5-HT reuptake inhibitors for treating visceral pain syndromes |
US20040115262A1 (en) * | 2002-07-29 | 2004-06-17 | Frank Jao | Formulations and dosage forms for controlled delivery of topiramate |
US20040151772A1 (en) * | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
ATE495732T1 (de) * | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
CA2520312C (en) * | 2003-03-26 | 2013-06-18 | Egalet A/S | Matrix compositions for controlled delivery of drug substances |
US20060177497A1 (en) | 2003-07-21 | 2006-08-10 | Bio Dar Ltd. | Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention |
BRPI0414311A (pt) | 2003-09-19 | 2008-03-04 | Penwest Pharmaceutical Co | formas de dosagem de liberação controlada |
WO2005065654A2 (en) | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Rosiglitazone formulations |
AU2006254554B2 (en) | 2005-06-03 | 2011-11-24 | Egalet Ltd | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
-
2004
- 2004-03-26 CA CA2520312A patent/CA2520312C/en not_active Expired - Fee Related
- 2004-03-26 DE DE602004025159T patent/DE602004025159D1/de not_active Expired - Lifetime
- 2004-03-26 ES ES04723523T patent/ES2307003T3/es not_active Expired - Lifetime
- 2004-03-26 JP JP2006504340A patent/JP4989217B2/ja not_active Expired - Fee Related
- 2004-03-26 DK DK04723523T patent/DK1610768T3/da active
- 2004-03-26 EP EP08158752A patent/EP1974726B1/de not_active Expired - Lifetime
- 2004-03-26 DE DE602004014747T patent/DE602004014747D1/de not_active Expired - Lifetime
- 2004-03-26 EP EP04723523A patent/EP1610768B1/de not_active Expired - Lifetime
- 2004-03-26 WO PCT/DK2004/000217 patent/WO2004084869A1/en active IP Right Grant
- 2004-03-26 AT AT04723523T patent/ATE399538T1/de active
- 2004-03-26 AT AT08158752T patent/ATE454886T1/de not_active IP Right Cessation
- 2004-03-26 US US10/550,685 patent/US8298581B2/en not_active Expired - Fee Related
- 2004-03-26 EP EP09179452.9A patent/EP2186510B1/de not_active Expired - Lifetime
-
2009
- 2009-12-18 US US12/642,416 patent/US20100166866A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2520312A1 (en) | 2004-10-07 |
US20100166866A1 (en) | 2010-07-01 |
US20070042044A1 (en) | 2007-02-22 |
ES2307003T3 (es) | 2008-11-16 |
JP4989217B2 (ja) | 2012-08-01 |
JP2006521301A (ja) | 2006-09-21 |
ATE454886T1 (de) | 2010-01-15 |
EP1610768B1 (de) | 2008-07-02 |
EP1974726B1 (de) | 2010-01-13 |
EP1974726A2 (de) | 2008-10-01 |
EP2186510B1 (de) | 2013-07-10 |
WO2004084869A1 (en) | 2004-10-07 |
US8298581B2 (en) | 2012-10-30 |
DK1610768T3 (da) | 2008-09-22 |
DE602004014747D1 (de) | 2008-08-14 |
EP1610768A1 (de) | 2006-01-04 |
ATE399538T1 (de) | 2008-07-15 |
EP2186510A3 (de) | 2010-06-09 |
EP1974726A3 (de) | 2008-11-05 |
CA2520312C (en) | 2013-06-18 |
EP2186510A2 (de) | 2010-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004025159D1 (de) | Matrixzubereitungen für die kontrollierte Darreichung von Arzneistoffen | |
US20190038570A1 (en) | Sublingual and buccal film compositions | |
EP3031445B1 (de) | Sublinguale und bukkale filmzusammensetzungen | |
ATE495732T1 (de) | Morphin-system mit kontrollierter freisetzung | |
US20190070100A1 (en) | Sublingual and buccal film compositions | |
CN1929819A (zh) | 递送活性剂的快速溶解膜 | |
JPH04504515A (ja) | 通気性バッキング | |
BRPI0514293A (pt) | sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga | |
WO2007112436A3 (en) | Use of polymeric materials with other substances for improved performance | |
US8298572B2 (en) | Adhesive pharmaceutical preparation containing bisoprolol | |
EP1968558B1 (de) | Ph-modulierte folien zur abgabe von wirkstoffen | |
CN1256627A (zh) | 固体微粒形成用组合物 | |
JP5749790B2 (ja) | 多層溶融押出フィルム | |
CN102711834B (zh) | 治疗hiv的可植入装置 | |
US10285910B2 (en) | Sublingual and buccal film compositions | |
CN101199494A (zh) | 一种防治晕动病贴片及其制备方法 | |
CN1927189A (zh) | 经皮吸收型药物制剂 | |
WO2016123696A1 (en) | Oral dosage film exhibiting enhanced mucosal penetration | |
JP3440284B2 (ja) | 皮膚貼付薬用支持体 | |
JPH09255566A (ja) | 経皮投与薬用支持体 | |
TWI674900B (zh) | 用於經皮輸送安非他命之組合物及方法 | |
JPS61167615A (ja) | 薬剤投与方法 | |
MXPA05012815A (es) | Peliculas basadas en oxido de polietileno y sistemas para suministro de fármacos elaborados con ellas. | |
McElroy et al. | General strategy for the synthesis of biologically active block copolymers | |
JPH09262944A (ja) | 経皮投与薬用支持体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: EGALET A/S, VAERLOESE, GB |
|
R082 | Change of representative |
Ref document number: 1974726 Country of ref document: EP Representative=s name: ZACCO DR. PETERS UND PARTNER, DE |